Discover the health-related quality of life findings from FRESCO-2¹, highlighting how FRUZAQLA^®2 supports stability and delays deterioration, as analyzed through patient-centered tools.

Learn more about FRESCO-2, the global, randomised, double-blind, multi-centric phase III pivotal FRUZAQLA®-study.